We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. ATLANTA — Patients in the RE-SONATE trial who extended ...

Patients with multiple myeloma are at increased risk for blood clots, especially in the first 6 to 12 months after treatment initiation. Many physicians advise no more than a daily aspirin to avoid ...

Phase I Dose Escalation, Pharmacokinetic and Pharmacodynamic Study of Naptumomab Estafenatox Alone in Patients With Advanced Cancer and With Docetaxel in Patients With Advanced Non–Small-Cell Lung ...

Venous thromboembolism rates among patients with advanced non-small cell lung cancer varied by treatment type, according to retrospective study results. Patients treated with platinum-based ...

Paul P. Dobesh, PharmD, explained that the approval of betrixaban was important for several reasons: VTE events continue to occur during hospitalization and following discharge, despite the standard ...

December 19, 2011 (San Diego, CA) — Data from the RECOVER II study confirms the safety and efficacy of dabigatran (Pradaxa, Boehringer Ingelheim) when compared with warfarin for the treatment of ...

The VTE rate ratios were significantly greater for all forms of hormonal contraception, except for progestin-only pills, compared with non-use. Venous thromboembolism (VTE) continues to be a risk ...

Abbreviations: VTE, venous thromboembolism; AL, acute leukemia; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; APL, acute promyelocytic leukemia. VTE ...

Venous thromboembolism (VTE) occurs when a blood clot, or thrombi, forms in a deep vein. VTE describes two separate, but often related conditions: deep vein thrombosis (DVT) and pulmonary embolism (PE ...

In contrast to the elevated risk of venous thromboembolism (VTE) observed in patients hospitalized with COVID-19, outpatients with SARS-CoV-2 infection do not appear to carry a greater risk, a study ...